Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00149981




Registration number
NCT00149981
Ethics application status
Date submitted
6/09/2005
Date registered
8/09/2005
Date last updated
9/09/2019

Titles & IDs
Public title
A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
Scientific title
A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
Secondary ID [1] 0 0
2004-001473-25
Secondary ID [2] 0 0
CRAD001A2401
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Organ Transplantation 0 0
Condition category
Condition code

Intervention/exposure
Study type
Expanded Access
Description of intervention(s) / exposure
Treatment: Drugs - everolimus (RAD)

Treatment: Drugs: everolimus (RAD)
Everolimus
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes

Eligibility
Key inclusion criteria
* Male or female recipients of solid organ transplants
* Subject is currently enrolled in an everolimus (RAD) trial sponsored by Novartis
* Currently on investigational drug everolimus (RAD) therapy
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Inability or unwillingness to comply with immunosuppressive regimen.
* Pregnancy.
* History of acute organ rejection within the last 3 months.

Other protocol-defined inclusion/exclusion criteria may apply.

Study design
Purpose of the study
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
NO_LONGER_AVAILABLE
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Camperdown
Recruitment hospital [2] 0 0
Novartis Investigative Site - Darlinghurst
Recruitment hospital [3] 0 0
Novartis Investigative Site - Woolloongabba
Recruitment hospital [4] 0 0
Novartis Investigative Site - Clayton
Recruitment hospital [5] 0 0
Novartis Investigative Site - Parkville
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
3168 - Clayton
Recruitment postcode(s) [5] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
North Dakota
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Pennsylvania
Country [22] 0 0
United States of America
State/province [22] 0 0
Rhode Island
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Utah
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
West Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Wisconsin
Country [30] 0 0
Belgium
State/province [30] 0 0
Bruxelles
Country [31] 0 0
Belgium
State/province [31] 0 0
Leuven
Country [32] 0 0
Brazil
State/province [32] 0 0
MG
Country [33] 0 0
Brazil
State/province [33] 0 0
RS
Country [34] 0 0
Brazil
State/province [34] 0 0
SP
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
British Columbia
Country [37] 0 0
Canada
State/province [37] 0 0
Nova Scotia
Country [38] 0 0
Canada
State/province [38] 0 0
Ontario
Country [39] 0 0
Canada
State/province [39] 0 0
Quebec
Country [40] 0 0
Canada
State/province [40] 0 0
Saskatchewan
Country [41] 0 0
Czechia
State/province [41] 0 0
Brno
Country [42] 0 0
Czechia
State/province [42] 0 0
Hradec Kralove
Country [43] 0 0
Czechia
State/province [43] 0 0
Ostrava-Poruba
Country [44] 0 0
Czechia
State/province [44] 0 0
Prague 4
Country [45] 0 0
France
State/province [45] 0 0
Brest
Country [46] 0 0
France
State/province [46] 0 0
Créteil
Country [47] 0 0
France
State/province [47] 0 0
Grenoble CEDEX
Country [48] 0 0
France
State/province [48] 0 0
Le Plessis Robinson
Country [49] 0 0
France
State/province [49] 0 0
Lyon
Country [50] 0 0
France
State/province [50] 0 0
Monpellier
Country [51] 0 0
France
State/province [51] 0 0
Nantes
Country [52] 0 0
France
State/province [52] 0 0
Paris
Country [53] 0 0
France
State/province [53] 0 0
Saint-Etienne
Country [54] 0 0
France
State/province [54] 0 0
Toulouse
Country [55] 0 0
France
State/province [55] 0 0
Tours
Country [56] 0 0
France
State/province [56] 0 0
Vandoeuvre-Les-Nancy
Country [57] 0 0
France
State/province [57] 0 0
Villejuif
Country [58] 0 0
Germany
State/province [58] 0 0
Bavaria
Country [59] 0 0
Germany
State/province [59] 0 0
Essen
Country [60] 0 0
Germany
State/province [60] 0 0
Hamburg
Country [61] 0 0
Germany
State/province [61] 0 0
Hannover
Country [62] 0 0
Germany
State/province [62] 0 0
Heidelberg
Country [63] 0 0
Germany
State/province [63] 0 0
Kiel
Country [64] 0 0
Italy
State/province [64] 0 0
MI
Country [65] 0 0
Italy
State/province [65] 0 0
PD
Country [66] 0 0
Italy
State/province [66] 0 0
PG
Country [67] 0 0
Italy
State/province [67] 0 0
PI
Country [68] 0 0
Italy
State/province [68] 0 0
PR
Country [69] 0 0
Italy
State/province [69] 0 0
PV
Country [70] 0 0
Italy
State/province [70] 0 0
RM
Country [71] 0 0
Italy
State/province [71] 0 0
SI
Country [72] 0 0
Italy
State/province [72] 0 0
SS
Country [73] 0 0
Italy
State/province [73] 0 0
VI
Country [74] 0 0
New Zealand
State/province [74] 0 0
Auckland
Country [75] 0 0
Norway
State/province [75] 0 0
Oslo
Country [76] 0 0
Poland
State/province [76] 0 0
Warszawa
Country [77] 0 0
Puerto Rico
State/province [77] 0 0
San Juan
Country [78] 0 0
Russian Federation
State/province [78] 0 0
Moscow
Country [79] 0 0
South Africa
State/province [79] 0 0
Johannesburg
Country [80] 0 0
Spain
State/province [80] 0 0
Andalucia
Country [81] 0 0
Spain
State/province [81] 0 0
Barcelona
Country [82] 0 0
Spain
State/province [82] 0 0
Cantabria
Country [83] 0 0
Spain
State/province [83] 0 0
Catalunya
Country [84] 0 0
Spain
State/province [84] 0 0
Comunidad Valenciana
Country [85] 0 0
Spain
State/province [85] 0 0
Vizcaya
Country [86] 0 0
Spain
State/province [86] 0 0
Madrid
Country [87] 0 0
Switzerland
State/province [87] 0 0
Bern
Country [88] 0 0
Switzerland
State/province [88] 0 0
Zuerich
Country [89] 0 0
Taiwan
State/province [89] 0 0
Taiwan ROC
Country [90] 0 0
Taiwan
State/province [90] 0 0
Taichung
Country [91] 0 0
Taiwan
State/province [91] 0 0
Taipei
Country [92] 0 0
Taiwan
State/province [92] 0 0
Taoyuan
Country [93] 0 0
United Kingdom
State/province [93] 0 0
London
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Manchester
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Facilitated access to everolimus until it is commercially available and reimbursable by appropriate parties
Trial website
https://clinicaltrials.gov/study/NCT00149981
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00149981